HIPRA is a biotechnological pharmaceutical company focused on prevention for animal and human health, with a broad range of highly innovative vaccines. With its claim “Building immunity for a healthier world”, HIPRA affirms its commitment to contributing with solutions that improve world health.

R&D projects are the basis of the knowledge. HIPRA has more than 50 years of experience dedicated to the research and development of different vaccines. With a unique organizational model, HIPRA controls all the processes of the value chain, generating singular know-how and becoming a reference in the research, production, and commercialization of biologics. HIPRA is the company that has launched the most biotech vaccines in the last 10 years, with a total of 22 vaccines.

HIPRA has a solid international presence in more than 40 countries, with its own subsidiaries, 3 R+D centres and 6 production centres strategically located in Europe (Spain) and America (Brazil).

Moreover, its extensive international distribution network keeps open marketing channels with nearly 100 other countries, thereby covering the 5 continents.

HIPRA is ranked 5th of the global leaders in the veterinary industry developing vaccines for Animal Health.

The beginnings of HIPRA date back to 1971 when a group of young entrepreneurs acquired a small laboratory in Madrid founded in 1954, called HIPRA (by the surnames of its former creators: Hidalgo and Prada), and moved to Amer (Girona). The year 1991, with a workforce of 100 people and a turnover of 10 million euros, was a crucial year in HIPRA’s history. A new highly motivated management team redefines the company’s expansion policy. Thus begins an important period of technical and commercial expansion. As of the year 2000, began the internationalization of HIPRA with the implementation of our own subsidiaries around the world. In 2009 the strategic positioning was refined with the clear mission of being the world leader in prevention, with differential and innovative products and, therefore, it stopped investing in pharmacological products. In 2020, and in a context of the COVID-19 pandemic, a new challenge was faced using its extensive experience in innovative vaccines, the development of the vaccine against this new virus based on recombinant protein. In 2021 the new Human Health division was created to develop new innovative products. The same year GoodGut was acquired, a biotechnological start-up dedicated to the research and development of diagnostic tests for digestive diseases.